Author:
Newell D R,Burtles S S,Fox B W,Jodrell D I,Connors T A
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Arbuck, SG (1996) Workshop on Phase I study design. Ann Oncol 7: 567–573.
2. Betteridge, RF, Bosanquet, AG & Gilby, ED (1990) Pharmacokinetics of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZQ, NSC224070) during a Phase I clinical trial. Eur J Cancer 26: 107–112.
3. Burtles, SS, Newell, DR, Henrar, REC & Connors, TA (1995) Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. Eur J Cancer 31A: 408–410.
4. Carmichael, J, Cantwell, BMJ, Mannix, KA, Veale, D, Elford, HL, Blackie, R, Kerr, DJ, Kaye, SB & Harris, AL (1990) A Phase I and pharmacokinetic study of didox administered by 36 hour infusion. Br J Cancer 61: 447–450.
5. Collins, JM, Zaharko, DS, Dedrick, RL & Chabner, BA (1986) Potential roles for preclinical pharmacology in Phase I clinical trials. Cancer Treat Rep 70: 73–80.
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献